[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
July 1999

Topical Amphotericin B for Cutaneous Leishmaniasis

Author Affiliations

Not Available

Arch Dermatol. 1999;135(7):856-857. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-7-dlt0799

Topical treatment of cutaneous leishmaniasis (CL) still poses a challenge. Amphotericin B, a potent antileishmanial antibiotic, is commonly administered intravenously. However, because amphotericin B is highly toxic and particularly nephrotoxic when given systemically, it is usually reserved for patients whose condition fails to respond to other treatments.1 We have recently found in a mouse model that amphotericin B administered topically as a complex either with cholesteryl sulfate or with phospholipids, in the presence of ethanol, can penetrate into the skin and cure cutaneous leishmaniasis in a localized manner using very low total drug concentrations.2 The aim of the present study was to assess the efficacy of an ethanolic amphotericin B–lipid formulation in patients with CL in a prospective, placebo-controlled trial.

First Page Preview View Large
First page PDF preview
First page PDF preview
×